Emergence of T cell immunosenescence in diabetic chronic kidney disease

  • PDF / 881,172 Bytes
  • 10 Pages / 595.276 x 790.866 pts Page_size
  • 56 Downloads / 183 Views

DOWNLOAD

REPORT


RESEARCH

Open Access

Emergence of T cell immunosenescence in diabetic chronic kidney disease Yen-Ling Chiu1,2,3, Wan-Chuan Tsai2,4, Ruo-Wei Hung2, I-Yu Chen2, Kai-Hsiang Shu2,5, Szu-Yu Pan2, Feng-Jung Yang6, Te-Tien Ting7, Ju-Ying Jiang8†, Yu-Sen Peng2,9,10† and Yi-Fang Chuang11*†

Abstract Background: Type 2 diabetes is an important challenge given the worldwide epidemic and is the most important cause of end-stage renal disease (ESRD) in developed countries. It is known that patients with ESRD and advanced renal failure suffer from immunosenescence and premature T cell aging, but whether such changes develop in patients with less severe chronic kidney disease (CKD) is unclear. Method: 523 adult patients with type 2 diabetes were recruited for this study. Demographic data and clinical information were obtained from medical chart review. Immunosenescence, or aging of the immune system was assessed by staining freshly-obtained peripheral blood with immunophenotyping panels and analyzing cells using multicolor flow cytometry. Result: Consistent with previously observed in the general population, both T and monocyte immunosenescence in diabetic patients positively correlate with age. When compared to diabetic patients with preserved renal function (estimated glomerular filtration rate > 60 ml/min), patients with impaired renal function exhibit a significant decrease of total CD3+ and CD4+ T cells, but not CD8+ T cell and monocyte numbers. Immunosenescence was observed in patients with CKD stage 3 and in patients with more severe renal failure, especially of CD8+ T cells. However, immunosenescence was not associated with level of proteinuria level or glucose control. In age, sex and glucose level-adjusted regression models, stage 3 CKD patients exhibited significantly elevated percentages of CD28−, CD127−, and CD57+ cells among CD8+ T cells when compared to patients with preserved renal function. In contrast, no change was detected in monocyte subpopulations as renal function declined. In addition, higher body mass index (BMI) is associated with enhanced immunosenescence irrespective of CKD status. Conclusion: The extent of immunosenescence is not significantly associated with proteinuria or glucose control in type 2 diabetic patients. T cells, especially the CD8+ subsets, exhibit aggravated characteristics of immunosenescence during renal function decline as early as stage 3 CKD. In addition, inflammation increases since stage 3 CKD and higher BMI drives the accumulation of CD8+CD57+ T cells. Our study indicates that therapeutic approaches such as weight loss may be used to prevent the emergence of immunosenescence in diabetes before stage 3 CKD. Keywords: Immunosenescence, CKD, T cell, Diabetes, BMI

* Correspondence: [email protected] † Ju-Ying Jiang, Yu-Sen Peng and Yi-Fang Chuang contributed equally to this work. 11 Institute of Public Health, School of Medicine, National Yang-Ming University, Taipei, Taiwan Full list of author information is available at the end of the article © The Author(s). 2020 Open Access